COVID-19, immunological risk profile (attached to the project presented by the VHIR IP R Pujol-Borrell)

At present, it is not known whether the minority of COVID-19 cases that evolve poorly are due to an excess or a defect in the innate or adaptive immune response or to joint dysregulation. There are tools not yet applied to be able to discern between the various immunological scenarios in which this infection develops. Objective: To generate algorithms to stratify patients by immunological risk profile applicable to the analysis of clinical trials with ongoing or future immunomodulars and, specifically, to support therapeutic strategies. Modules 1) daily collection and analysis of inflammation, coagulation, immunology and microbiology parameters as well as biochemistry in relation to the origins of the samples and the demographic data of the patients, evolutionary follow-up and progressive assessment of the most predictive indices; 2) Measurement of the level of 18 cytokines and 32 lymphocyte populations in 120 patients; 3) Generation of prognostic and therapeutic orientation algorithm; 4) Identification of the activated response pathways. Support modules include generating sample collections, clinical data extraction, and statistical analysis.